Platform For Clinical Trials Articles & Analysis: Older
14 news found
The two new business units will use Cellworks’ biosimulation platform and Computational Biology Model (CBM) to predict responses to pharmaceutical interventions in silico, thereby streamlining the clinical trial process by identifying the right patients more rapidly, which in turn reduces the time and expense of developing successful ...
xCures, Inc., a clinical study platform provider, and Oblato, Inc., a biotechnology company, are pleased to announce the availability of OKN-007 through an intermediate size expanded access program (iEAP) for eligible patients with pediatric diffuse midline glioma (DMG), inclusive of diffuse intrinsic pontine glioma (DIPG). ...
ByxCures
Sallés joins the Kallyope senior leadership team as the company advances its pioneering drug discovery platform, clinical trials, and pipeline of multiple programs modulating gut-brain axis signaling across a broad range of therapeutic areas. ...
Kallyope, Inc., a leading biotechnology company focused on identifying and developing therapeutics involving the gut-brain axis, today announced the appointments of George Shiebler as General Counsel and Anita Kawatra as Executive Vice President, Corporate Affairs, to help steer the company as it advances its pioneering drug discovery platform, clinical ...
Embedding this AI technology within PathPresenter’s emerging ClinPx platform – a scanner-agnostic digital pathology workflow solution – could accelerate the adoption of AI tools within clinical workflows. ...
The funds will be used to advance the company’s pioneering drug discovery platform, clinical trials, and pipeline of multiple programs across a broad range of therapeutic areas. ...
Initial clinical data from the trial are expected in 2022. EO2463 is an innovative, off-the-shelf microbiome-peptide based cancer vaccine that combines four microbiome-peptides of B lymphocyte-specific lineage markers. ...
ByEnterome
Novadiscovery (“NOVA”), a leading health tech company offering JINKO, a best-in-class clinical trial simulation platform to predict drug efficacy and optimize clinical trial development, today announces that it has entered into a new collaboration with “Takeda Pharmaceutical Company Limited ...
Novadiscovery (“NOVA”), a leading health tech company offering JINKO, a best-in-class clinical trial simulation platform to predict drug efficacy and optimize clinical trial development, today announces that it has raised €2.5 million in a Series A2 financing round from Sanofi. The funds will be ...
HistoSonics announced today that it has received approval to initiate the company’s second European clinical trial of its new platform technology, which is designed to use the science of histotripsy to mechanically destroy targeted liver tumors, from outside of the body. ...
Novadiscovery, a leading health tech company offering a best-in-class clinical trial simulation platform, Jinko®, to predict drug efficacy and optimize clinical trial development, today announces that it has entered into a collaboration with Janssen France to provide in silico based decision support for its ...
Food and Drug Administration (FDA) to begin a clinical trial of its new platform technology, which is designed to use the science of histotripsy to mechanically destroy targeted liver tissue and tumors, from outside of the body. The study is a multi-center, open label and single arm trial to evaluate the safety and efficacy in ...
Novadiscovery, a leading health tech company using in silico clinical trials to predict drug efficacy and optimize clinical trial development, today announces that it has strengthened its leadership team with two senior appointments. ...
The mean diagnostic age is around 8 years of age although the first clinical signs appear during the first year of life. Patients’ quality of life is significantly improved by an adapted diet. Being able to come up with an early diagnosis is therefore crucial for improving clinical practice in this disease” comments Vincent Petit, co-founder and CEO ...